Natural History of Human Papillomavirus Infections Involving Anal, Penile, and Oral Sites Among HIV-Positive Men

Videla, Sebastián; Darwich, Laila; Cañadas, MariPaz; Coll, J; Piñol, Marta; Cuyàs, Francesc García; Molina‐López, Rafael A.; Cobarsí, Patricia; Clotet, Bonaventura; Sirera, Guillem

doi:10.1097/olq.0b013e31827e87bd

Cited by 103 publications

(138 citation statements)

References 29 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Although biennial screening for AIN in HIV negative MSM has been suggested (302) it is not routinely practiced and cost effectiveness is unproven. MSM with HIV are reported to have a higher frequency of prevalent high risk HPV strains, persistence of HPV, incident anal dysplasia, progression to and relapse of anal intraepithelial neoplasia (AIN) and anal cancer than heterosexual men and women (303,304 (310), others report no effect with ART (311).…”

Section: Anal Dysplasiamentioning

confidence: 99%

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

et al. 2018

View full text Add to dashboard Cite

This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is likely to be of relevance in all sexual health settings, including general practice and Contraception and Sexual Health (CASH) services, where men who have sex with men (MSM) seek sexual health care or where addressing the sexual health needs of MSM may have public health benefits. For the purposes of this document, MSM includes all gay, bisexual and all other males who have sex with other males and both cis and trans men. This document does not provide guidance on the treatment of particular conditions where this is covered in other British Association for Sexual Health and HIV (BASHH) Guidelines but outlines best practice in multiple aspects of the sexual health care of MSM. Where prevention of sexually transmitted infections including HIV can be addressed as an integral part of clinical care, this is consistent with the concept of combination prevention and is included. The document is designed primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design and delivery of services with the aim of supporting clinicians and commissioners in providing effective services. Methodology This document was produced in accordance with the guidance set out in the BASHH CEG’s document ‘Framework for guideline development and assessment’ published in 2010 at http://www.bashh.org/guidelines and with reference to the Agree II instrument. Following the production of the updated framework in April 2015, the GRADE system for assessing evidence was adopted and the draft recommendations were regraded. Search strategy (see also Appendix 1) Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given to peer-reviewed papers published in scientific journals, although for many issues evidence includes conference abstracts listed on the Embase database. In addition, for ‘Identification of problematic recreational drug and alcohol use’ section and ‘Sexual problems and dysfunctions in MSM’ section, searches included PsycINFO. Methods Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was given to randomised controlled trial and systematic review evidence, and recommendations made and graded on the basis of best available evidence. Piloting and feedback The first draft of the guideline was circulated to the writing group and to a small group of relevant experts, third sector partners and patient representatives who were invited to comment on the whole document and specifically on particular sections. The revised draft was reviewed by the CEG and then reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. The final draft was piloted before publication. Guideline update The guidelines will be reviewed and revised in five years’ time, 2022.

show abstract

Section: Anal Dysplasiamentioning

confidence: 99%

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

et al. 2018

View full text Add to dashboard Cite

show abstract

“…124 The majority of research on HPV-related disease in MSM has involved DNA detection of prevalent anal HPV infection. There are fewer prospective data on the frequency of acquisition and duration of anal HPV infection in MSM, 125,126 and studies of penile and pharyngeal HPV infection in MSM are rare. 123,127 A small number of studies have assessed HPV seroprevalence in MSM 125 but this is unlikely to be a useful clinical diagnostic tool due to the low sensitivity of HPV serology as a marker of HPV infection.…”

Section: Human Papillomavirusmentioning

confidence: 99%

Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: a review of the evidence

et al. 2014

View full text Add to dashboard Cite

Abstract.Men who have sex with men (MSM) in Australia and overseas are disproportionately affected by sexually transmissible infections (STIs), including HIV. Many STIs are asymptomatic, so regular testing and management of asymptomatic MSM remains an important component of effective control. We reviewed articles from January 2009-May 2013 to inform the 2014 update of the 2010 Australian testing guidelines for asymptomatic MSM. Key changes include: a recommendation for pharyngeal chlamydia (Chlamydia trachomatis) testing, use of nucleic acid amplification tests alone for gonorrhoea (Neisseria gonorrhoeae) testing (without gonococcal culture), more frequent (up to four times a year) gonorrhoea and chlamydia testing in sexually active HIV-positive MSM, time required since last void for chlamydia first-void urine collection specified at 20 min, urethral meatal swab as an alternative to first-void urine for urethral chlamydia testing, and the use of electronic reminders to increase STI and HIV retesting rates among MSM.

show abstract

“…Risk analysis for the detection of anal HPV has been reported mainly in at-risk groups, such as men who have sex with men [26][27][28] and HIV-infected men [18,20,29]. Risk factors include HIV infection, low CD4 counts, anal condylomata, and history of RAI.…”

Section: Discussionmentioning

confidence: 99%

“…However, data on HPV at extra-genital sites are rare and limited to at-risk groups, such as men who have sex with men [15], transplant recipients [16], sex workers [17] and HIV-infected individuals [18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus infection and associated lesions in the cervix, anal canal, and mouth of HIV-uninfected women with different HIV risk status in Barcelona

Darwich¹,

Videla²,

Ornelas³

et al. 2017

Virol Res Rev

Self Cite

View full text Add to dashboard Cite

Objective: Data on human papillomavirus (HPV) infections and their related lesions appearing simultaneously at different anatomical sites are scarce. Our aim was to provide information about HPV infection and lesions of the cervix, anal canal, and mouth of women at different risk conditions to be infected by HIV. Methods:Cross-sectional study. Detection and genotyping of HPV infections were done by multiplex PCR, and the cytology by Papanicolaou test. HPV Prevalence and associated risk factors were estimated. Results:The study included 108 women (44 at risk and 64 with no risk of HIV-infection). The highest prevalence of HPV infection was found in the anal canal (26% at HIV-risk versus 28% with no risk group, p=0.79), followed by the cervix (14% versus 28%, p=0.07) and the oral cavity (7% versus 9%, p=0.64). HPV16 was the most prevalent type in cervix (5.6%) and anus (8.6%) for both groups but HPV52 (4.5%) was the most frequent type in the mouth of the at-risk group. Interestingly, women from the at HIV-risk group presented higher prevalence of anal infection involving a wider range of different high-risk oncogenic HPV-types. Concomitant HPV infections with HPV16, 18 and other oncogenic types (HPV56, 59) were found in 3.1% of women (all three areas) and 7.1% (cervix and anal canal). As regards HPV-related lesions, no statistical differences were observed between groups, although women at HIV-risk had higher proportion of anal abnormalities (18.4% versus 8.2%, p=0.19). Finally, cervical HPV-infection was significantly associated with presence of cervical or anal condylomata and alcohol consumption and anal HPV-infection with smoking and RAI. Conclusion:Both women at risk of HIV-infection or with anogenital warts presented a wider range of HPV-oncogenic types in the anal canal, resulting good candidates for HPV anal screening and monitoring programs.

show abstract

Natural History of Human Papillomavirus Infections Involving Anal, Penile, and Oral Sites Among HIV-Positive Men

Cited by 103 publications

References 29 publications

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: a review of the evidence

Human papillomavirus infection and associated lesions in the cervix, anal canal, and mouth of HIV-uninfected women with different HIV risk status in Barcelona

Contact Info

Product

Resources

About